| # | Drug | Count |
|---|---|---|
| 0 | NIVOLUMAB | 7046 |
| 1 | ENZALUTAMIDE | 4495 |
| 2 | PEMBROLIZUMAB | 4361 |
| 3 | EVEROLIMUS | 3689 |
| 4 | CARBOPLATIN | 2888 |
| 5 | DEXAMETHASONE | 2696 |
| 6 | CAPECITABINE | 2566 |
| 7 | IPILIMUMAB | 2512 |
| 8 | LETROZOLE | 2224 |
| 9 | FULVESTRANT | 2153 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | AFATINIB | 1429 | 0.2700 |
| 1 | CERITINIB | 364 | 0.1953 |
| 2 | GEFITINIB | 1448 | 0.1874 |
| 3 | RUCAPARIB | 1002 | 0.1570 |
| 4 | PRALATREXATE | 66 | 0.1560 |
| 5 | OLAPARIB | 1048 | 0.1527 |
| 6 | PEMBROLIZUMAB | 4361 | 0.1454 |
| 7 | RAMUCIRUMAB | 541 | 0.1433 |
| 8 | OSIMERTINIB | 1383 | 0.1319 |
| 9 | NIVOLUMAB | 7046 | 0.1284 |
| # | Drug class | Count |
|---|---|---|
| 0 | Kinase Inhibitor [EPC] | 12062 |
| 1 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 11419 |
| 2 | Corticosteroid [EPC] | 5276 |
| 3 | Platinum-based Drug [EPC] | 5068 |
| 4 | Nucleoside Metabolic Inhibitor [EPC] | 4856 |
| 5 | Androgen Receptor Inhibitor [EPC] | 4808 |
| 6 | mTOR Inhibitor Immunosuppressant [EPC] | 3734 |
| 7 | Aromatase Inhibitor [EPC] | 3556 |
| 8 | Microtubule Inhibitor [EPC] | 3519 |
| 9 | Nonsteroidal Anti-inflammatory Drug [EPC] | 2864 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] | 541 | 0.1433 |
| 1 | Estrogen Receptor Antagonist [EPC] | 2153 | 0.1273 |
| 2 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 11419 | 0.1188 |
| 3 | CTLA-4-directed Blocking Antibody [EPC] | 2512 | 0.0985 |
| 4 | Androgen Receptor Inhibitor [EPC] | 4808 | 0.0853 |
| 5 | Radioactive Therapeutic Agent [EPC] | 10 | 0.0847 |
| 6 | Programmed Death Ligand-1 Blocker [EPC] | 514 | 0.0816 |
| 7 | Poly(ADP-Ribose) Polymerase Inhibitor [EPC] | 1376 | 0.0802 |
| 8 | SLAMF7-directed Immunostimulatory Antibody [EPC] | 199 | 0.0540 |
| 9 | Aromatase Inhibitor [EPC] | 3556 | 0.0510 |